MANKIND PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,112 INR | +1.00% |
|
-5.59% | +6.51% |
| 05-16 | Transcript : Mankind Pharma Limited, Q4 2024 Earnings Call, May 16, 2024 | |
| 05-16 | Mankind Pharma's Consolidated Profit Jumps in Fiscal Q4 | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 | 103B 1.24B 1.69B | Sales 2025 * | 116B 1.39B 1.9B | Capitalization | 846B 10.16B 13.82B |
|---|---|---|---|---|---|
| Net income 2024 | 19.13B 230M 312M | Net income 2025 * | 22.22B 267M 363M | EV / Sales 2024 | 8.92 x |
| Net cash position 2024 * | 25.25B 303M 413M | Net cash position 2025 * | 52.14B 626M 852M | EV / Sales 2025 * | 6.84 x |
| P/E ratio 2024 |
48.3
x | P/E ratio 2025 * |
38.1
x | Employees | 18,468 |
| Yield 2024 * |
0.32% | Yield 2025 * |
0.27% | Free-Float | 19.92% |
More Fundamentals
* Assessed data
More news
Latest transcript on Mankind Pharma Limited
More recommendations
| 1 day | +1.00% | ||
| 1 week | -5.59% | ||
| Current month | -10.69% | ||
| 1 month | -9.66% | ||
| 3 months | -4.94% | ||
| 6 months | +9.98% | ||
| Current year | +6.51% |
1 week
2 060.00
2 299.00
1 month
2 060.002 490.00
Current year
1 980.002 490.00
1 year
1 242.002 490.00
3 years
1 242.002 490.00
5 years
1 242.002 490.00
10 years
1 242.002 490.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sheetal Arora
CEO | Chief Executive Officer | 48 | 07-09-20 |
Ashutosh Dhawan
DFI | Director of Finance/CFO | 55 | 16-06-16 |
Pradeep Chugh
CMP | Compliance Officer | - | 16-09-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vivek Kalra
BRD | Director/Board Member | 60 | 22-07-31 |
Vijaya Sampath
BRD | Director/Board Member | 71 | 22-07-31 |
Surendra Lunia
BRD | Director/Board Member | 61 | 15-02-18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-18 | 2,112 | +1.00% | 38,068 |
| 24-05-17 | 2,091 | -0.09% | 1,545,240 |
| 24-05-16 | 2,093 | -4.48% | 3,462,277 |
| 24-05-15 | 2,191 | -2.58% | 849,117 |
| 24-05-14 | 2,249 | +3.18% | 402,102 |
Delayed Quote NSE India S.E., May 18, 2024 at 03:15 am
More quotes
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.
Sector
Pharmaceuticals
Calendar
2024-07-30
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
2,112
INR
Average target price
2,209
INR
Spread / Average Target
+4.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.51% | 10.05B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- MANKIND Stock
